205 related articles for article (PubMed ID: 14751176)
1. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Smith JA; Brown J; Martin MC; Ramondetta LM; Wolf JK
Gynecol Oncol; 2004 Jan; 92(1):314-9. PubMed ID: 14751176
[TBL] [Abstract][Full Text] [Related]
2. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Smith JA; Gaikwad A; Ramondetta LM; Wolf JK; Brown J
Gynecol Oncol; 2006 Nov; 103(2):518-22. PubMed ID: 16690105
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
5. In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
Zanellato I; Boidi CD; Lingua G; Betta PG; Orecchia S; Monti E; Osella D
Cancer Chemother Pharmacol; 2011 Feb; 67(2):265-73. PubMed ID: 20369238
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and platinum combinations in pancreatic cancer.
Philip PA
Cancer; 2002 Aug; 95(4 Suppl):908-11. PubMed ID: 12209670
[TBL] [Abstract][Full Text] [Related]
7. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.
Kanzawa F; Akiyama Y; Saijo N; Nishio K
Lung Cancer; 2003 Jun; 40(3):325-32. PubMed ID: 12781432
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in the treatment of ovarian cancer.
Hansen SW; Tuxen MK; Sessa C
Ann Oncol; 1999; 10 Suppl 1():51-3. PubMed ID: 10219453
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine in the treatment of ovarian cancer.
Hansen SW
Int J Gynecol Cancer; 2001; 11 Suppl 1():39-41. PubMed ID: 11489002
[TBL] [Abstract][Full Text] [Related]
11. Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Harper P
Semin Oncol; 2003 Aug; 30(4 Suppl 10):2-12. PubMed ID: 12917815
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine in non-small cell lung cancer.
Crinò L; Cappuzzo F
Expert Opin Pharmacother; 2002 Jun; 3(6):745-53. PubMed ID: 12036414
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
14. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
17. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
[TBL] [Abstract][Full Text] [Related]
18. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Hong YB; Kim JS; Yi YW; Seong YS; Bae I
Pancreas; 2012 Apr; 41(3):496-8. PubMed ID: 22415672
[No Abstract] [Full Text] [Related]
19. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Edelman MJ; Quam H; Mullins B
Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
[TBL] [Abstract][Full Text] [Related]
20. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]